Analysts forecast that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will post ($0.20) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Celldex Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.20) and the highest estimate coming in at ($0.19). Celldex Therapeutics posted earnings per share of ($0.30) during the same quarter last year, which indicates a positive year over year growth rate of 33.3%. The firm is expected to report its next earnings results on Tuesday, March 13th.
According to Zacks, analysts expect that Celldex Therapeutics will report full-year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.07) to ($0.86). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.90) per share, with EPS estimates ranging from ($1.09) to ($0.59). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Celldex Therapeutics.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.07. The firm had revenue of $3.90 million during the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The firm’s quarterly revenue was up 77.3% on a year-over-year basis. During the same period last year, the company posted ($0.29) EPS.
Several brokerages have recently commented on CLDX. HC Wainwright reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. ValuEngine cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. WBB Securities reaffirmed a “buy” rating and issued a $10.00 target price on shares of Celldex Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 price objective on shares of Celldex Therapeutics in a report on Tuesday, September 26th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $7.05.
Celldex Therapeutics (NASDAQ CLDX) traded up $0.10 on Thursday, hitting $3.03. Celldex Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $4.07.
A number of hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new position in shares of Celldex Therapeutics in the third quarter valued at approximately $101,000. OxFORD Asset Management LLP acquired a new position in shares of Celldex Therapeutics during the 3rd quarter worth about $122,000. Dimensional Fund Advisors LP boosted its stake in shares of Celldex Therapeutics by 3.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 861,790 shares of the biopharmaceutical company’s stock worth $2,465,000 after buying an additional 29,604 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of Celldex Therapeutics during the 3rd quarter worth about $242,000. Finally, Ameriprise Financial Inc. boosted its stake in shares of Celldex Therapeutics by 15.6% during the 3rd quarter. Ameriprise Financial Inc. now owns 441,411 shares of the biopharmaceutical company’s stock worth $1,263,000 after buying an additional 59,629 shares during the last quarter. 52.55% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “-$0.20 Earnings Per Share Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://ledgergazette.com/2017/12/10/0-20-earnings-per-share-expected-for-celldex-therapeutics-inc-cldx-this-quarter.html.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.